{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:57:19Z","timestamp":1780433839550,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Exp Biol Med"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10517-024-06093-0","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:01:47Z","timestamp":1715274107000},"page":"703-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"176","author":[{"given":"A. V.","family":"Razumovskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Silkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Nikulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Tonevitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Ya.","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"6093_CR1","unstructured":"Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem. Biol. Letters. 2023;10(1):451. URL: https:\/\/pubs.thesciencein.org\/journal\/index.php\/cbl\/article\/view\/451"},{"key":"6093_CR2","doi-asserted-by":"publisher","first-page":"1190637","DOI":"10.3389\/fbioe.2023.1190637","volume":"11","author":"X He","year":"2023","unstructured":"He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G, Cai S, Mo S, Peng J. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Front. Bioeng. Biotechnol. 2023;11:1190637. doi: https:\/\/doi.org\/10.3389\/fbioe.2023.1190637","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"16","key":"6093_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/CM9.0000000000000882","volume":"133","author":"DB Ji","year":"2020","unstructured":"Ji DB, Wu AW. Organoid in colorectal cancer: progress and challenges. Chin. Med. J. (Engl). 2020;133(16):1971-1977. doi: https:\/\/doi.org\/10.1097\/CM9.0000000000000882","journal-title":"Chin. Med. J. (Engl)"},{"key":"6093_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.gde.2018.09.001","volume":"52","author":"N Sasaki","year":"2018","unstructured":"Sasaki N, Clevers H. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology. Curr. Opin. Genet. Dev. 2018;52:117-122. doi: https:\/\/doi.org\/10.1016\/j.gde.2018.09.001","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"7","key":"6093_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrd4253","volume":"13","author":"DR Pattabiraman","year":"2014","unstructured":"Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells \u2014 what challenges do they pose? Nat. Rev. Drug Discov. 2014;13(7):497-512. doi: https:\/\/doi.org\/10.1038\/nrd4253","journal-title":"Nat. Rev. Drug Discov."},{"key":"6093_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-018-0024-3","volume":"556","author":"SF Roerink","year":"2018","unstructured":"Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, Mitchell TJ, Grossmann S, Lightfoot H, Egan DA, Pronk A, Smakman N, van Gorp J, Anderson E, Gamble SJ, Alder C, van de Wetering M, Campbell PJ, Stratton MR, Clevers H. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature. 2018;556:457-462. doi: https:\/\/doi.org\/10.1038\/s41586-018-0024-3","journal-title":"Nature."},{"issue":"4","key":"6093_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","volume":"14","author":"CJ Punt","year":"2017","unstructured":"Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 2017;14(4):235-246. doi: https:\/\/doi.org\/10.1038\/nrclinonc.2016.171","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"6093_CR8","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/cancers13112657","volume":"13","author":"A Barb\u00e1chano","year":"2021","unstructured":"Barb\u00e1chano A, Fern\u00e1ndez-Barral A, Bustamante-Madrid P, Prieto I, Rodr\u00edguez-Salas N, Larriba MJ, Mu\u00f1oz A. Organoids and colorectal cancer. Cancers (Basel). 2021;13(11):2657. doi: https:\/\/doi.org\/10.3390\/cancers13112657","journal-title":"Cancers (Basel)."},{"issue":"3","key":"6093_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100103","volume":"6","author":"SN Ooft","year":"2021","unstructured":"Ooft SN, Weeber F, Schipper L, Dijkstra KK, McLean CM, Kaing S, van de Haar J, Prevoo W, van Werkhoven E, Snaebjornsson P, Hoes LR, Chalabi M, van der Velden D, van Leerdam M, Boot H, Grootscholten C, Huitema ADR, Bloemendal HJ, Cuppen E, Voest EE. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open. 2021;6(3):100103. doi: https:\/\/doi.org\/10.1016\/j.esmoop.2021.100103","journal-title":"ESMO Open."},{"key":"6093_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.815067","volume":"10","author":"L Luo","year":"2022","unstructured":"Luo L, Ma Y, Zheng Y, Su J, Huang G. Application progress of organoids in colorectal cancer. Front. Cell Dev. Biol. 2022;10:815067. doi: https:\/\/doi.org\/10.3389\/fcell.2022.815067","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"6093_CR11","doi-asserted-by":"publisher","first-page":"101042831770551","DOI":"10.1177\/1010428317705510","volume":"39","author":"MR Sadeghi","year":"2017","unstructured":"Sadeghi MR, Jeddi F, Soozangar N, Somi MH, Samadi N. The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance. Tumour Biol. 2017; 39(6):1010428317705510. doi: https:\/\/doi.org\/10.1177\/1010428317705510","journal-title":"Tumour Biol."},{"issue":"4","key":"6093_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tibs.2008.12.008","volume":"34","author":"JD Hayes","year":"2009","unstructured":"Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 2009;34(4):176-188. doi: https:\/\/doi.org\/10.1016\/j.tibs.2008.12.008","journal-title":"Trends Biochem. Sci."},{"issue":"10","key":"6093_CR13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/biom10101365","volume":"10","author":"L Torrente","year":"2020","unstructured":"Torrente L, Maan G, Oumkaltoum Rezig A, Quinn J, Jackson A, Grilli A, Casares L, Zhang Y, Kulesskiy E, Saarela J, Bicciato S, Edwards J, Dinkova-Kostova AT, de la Vega L. High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro. Biomolecules. 2020;10(10):1365. doi: https:\/\/doi.org\/10.3390\/biom10101365","journal-title":"Biomolecules."},{"key":"6093_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/B978-0-12-398339-8.00002-1","volume":"63","author":"IM Copple","year":"2012","unstructured":"Copple IM. The Keap1-Nrf2 cell defense pathway \u2014 a promising therapeutic target? Adv. Pharmacol. 2012;63:43-79. doi: https:\/\/doi.org\/10.1016\/B978-0-12-398339-8.00002-1","journal-title":"Adv. Pharmacol."},{"issue":"5","key":"6093_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox10050743","volume":"10","author":"DY Lee","year":"2021","unstructured":"Lee DY, Song MY, Kim EH. Role of oxidative stress and Nrf2\/KEAP1 signaling in colorectal cancer: mechanisms and therapeutic perspectives with phytochemicals. Antioxidants (Basel). 2021;10(5):743. doi: https:\/\/doi.org\/10.3390\/antiox10050743","journal-title":"Antioxidants (Basel)."},{"issue":"4","key":"6093_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","volume":"108","author":"D Ren","year":"2011","unstructured":"Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl Acad. Sci. USA. 2011;108(4):1433-1438. doi: https:\/\/doi.org\/10.1073\/pnas.1014275108","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"7","key":"6093_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/carcin\/bgv061","volume":"36","author":"C To","year":"2015","unstructured":"To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A\/J model of lung carcinogenesis. Carcinogenesis. 2015;36(7):769-781. doi: https:\/\/doi.org\/10.1093\/carcin\/bgv061","journal-title":"Carcinogenesis."},{"issue":"1","key":"6093_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/antiox12010116","volume":"12","author":"JA Moerland","year":"2023","unstructured":"Moerland JA, Leal AS, Lockwood B, Demireva EY, Xie H, Krieger-Burke T, Liby KT. The triterpenoid CDDO-methyl ester redirects macrophage polarization and reduces lung tumor burden in a Nrf2-dependent manner. Antioxidants (Basel). 2023;12(1):116. doi: https:\/\/doi.org\/10.3390\/antiox12010116","journal-title":"Antioxidants (Basel)."},{"key":"6093_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.777114","volume":"12","author":"A Poloznikov","year":"2021","unstructured":"Poloznikov A, Nikulin S, Bolotina L, Kachmazov A, Raigorodskaya M, Kudryavtseva A, Bakhtogarimov I, Rodin S, Gaisina I, Topchiy M, Asachenko A, Novosad V, Tonevitsky A, Alekseev B. 9-ING-41, a small molecule inhibitor of GSK-3\u03b2, potentiates the effects of chemotherapy on colorectal cancer cells. Front. Pharmacol. 2021;12:777114. doi: https:\/\/doi.org\/10.3389\/fphar.2021.777114","journal-title":"Front. Pharmacol."},{"key":"6093_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.biochi.2020.10.007","volume":"179","author":"SV Nikulin","year":"2020","unstructured":"Nikulin SV, Alekseev BY, Sergeeva NS, Karalkin PA, Nezhurina EK, Kirsanova VA, Sviridova IK, Akhmedova SA, Volchenko NN, Bolotina LV, Osipyants AI, Hushpulian DM, Topchiy MA, Asachenko AF, Koval AP, Shcherbo DS, Kiselev VI, Mikhaylenko DS, Schumacher U, Poloznikov AA. Breast cancer organoid model allowed to reveal potentially beneficial combinations of 3,3\u2019-diindolylmethane and chemotherapy drugs. Biochimie. 2020;179:217-227. doi: https:\/\/doi.org\/10.1016\/j.biochi.2020.10.007","journal-title":"Biochimie."},{"issue":"14","key":"6093_CR21","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin. Cancer Res. 2017;23(14):3489-3498. doi: https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3083","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"6093_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods. 2016;13(6):521-527. doi: https:\/\/doi.org\/10.1038\/nmeth.3853","journal-title":"Nat. Methods."},{"key":"6093_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin. Cancer Biol. 2020;66:89-100. doi: https:\/\/doi.org\/10.1016\/j.semcancer.2019.03.002","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"6093_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2020009404","volume":"138","author":"A Schmitt","year":"2021","unstructured":"Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, Zapukhlyak M, Berning P, Br\u00e4ndle M, Jarboui MA, Sch\u00f6nfeld C, Boldt K, Rosenwald A, Ott G, Grau M, Klener P, Vockova P, Lengerke C, Lenz G, Schulze-Osthoff K, Hailfinger S. Dimethyl fumarate induces ferroptosis and impairs NF-\u03baB\/STAT3 signaling in DLBCL. Blood. 2021;138(10):871-884. doi: https:\/\/doi.org\/10.1182\/blood.2020009404","journal-title":"Blood."},{"issue":"10","key":"6093_CR25","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/antiox11101859","volume":"11","author":"F Ballout","year":"2022","unstructured":"Ballout F, Lu H, Chen Z, Hu T, Chen L, Washington MK, El-Rifai W, Peng D. Targeting NRF2 sensitizes esophageal adenocarcinoma cells to cisplatin through induction of ferroptosis and apoptosis. Antioxidants (Basel). 2022;11(10):1859. doi: https:\/\/doi.org\/10.3390\/antiox11101859","journal-title":"Antioxidants (Basel)."},{"issue":"8","key":"6093_CR26","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1073\/pnas.1819728116","volume":"116","author":"Z Wu","year":"2019","unstructured":"Wu Z, Geng Y, Lu X, Shi Y, Wu G, Zhang M, Shan B, Pan H, Yuan J. Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl Acad. Sci. USA. 2019;116(8):2996-3005. doi: https:\/\/doi.org\/10.1073\/pnas.1819728116","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6093_CR27","doi-asserted-by":"publisher","first-page":"3469840","DOI":"10.1155\/2020\/3469840","volume":"2020","author":"R Li","year":"2020","unstructured":"Li R, Zhang J, Zhou Y, Gao Q, Wang R, Fu Y, Zheng L, Yu H. Transcriptome investigation and in vitro verification of curcumin-induced HO-1 as a feature of ferroptosis in breast cancer cells. Oxid Med. Cell. Longev. 2020;2020:3469840. doi: https:\/\/doi.org\/10.1155\/2020\/3469840","journal-title":"Oxid Med. Cell. Longev."},{"issue":"4","key":"6093_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s10637-017-0557-6","volume":"36","author":"HY Liu","year":"2018","unstructured":"Liu HY, Tuckett AZ, Fennell M, Garippa R, Zakrzewski JL. Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation. Invest. New Drugs. 2018;36(4):590-600. doi: https:\/\/doi.org\/10.1007\/s10637-017-0557-6","journal-title":"Invest. New Drugs."},{"issue":"2","key":"6093_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00280-011-1712-y","volume":"69","author":"G Speranza","year":"2012","unstructured":"Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A. Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. Cancer Chemother. Pharmacol. 2012;69(2):431-438. doi: https:\/\/doi.org\/10.1007\/s00280-011-1712-y","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3\u20134","key":"6093_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.9738\/INTSURG-D-20-00005.1","volume":"104","author":"CH Chang","year":"2019","unstructured":"Chang CH, Tsai HP, Kuo SH, Loh JK, Lin CJ, Lin CL, Kwan AL. Synthetic triterpenoid CDDO-Me inhibits proliferation, migration, and invasion in GBM8401 and GBM8901. Int. Surg. 2019;104(3-4):90-98. doi: https:\/\/doi.org\/10.9738\/INTSURG-D-20-00005.1","journal-title":"Int. Surg."},{"issue":"22","key":"6093_CR31","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.3390\/molecules24224097","volume":"24","author":"R Borella","year":"2019","unstructured":"Borella R, Forti L, Gibellini L, De Gaetano A, De Biasi S, Nasi M, Cossarizza A, Pinti M. Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids. Molecules. 2019;24(22):4097. doi: https:\/\/doi.org\/10.3390\/molecules24224097","journal-title":"Molecules."},{"issue":"9","key":"6093_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00210-022-02270-y","volume":"395","author":"B Ard\u0131l","year":"2022","unstructured":"Ard\u0131l B, Alper M. Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. Naunyn Schmiedebergs Arch. Pharmacol. 2022;395(9):1109-1123. doi: https:\/\/doi.org\/10.1007\/s00210-022-02270-y","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"3","key":"6093_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3892\/ijmm.2018.3372","volume":"41","author":"HM Chen","year":"2018","unstructured":"Chen HM, Lai ZQ, Liao HJ, Xie JH, Xian YF, Chen YL, Ip SP, Lin ZX, Su ZR. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int. J. Mol. Med. 2018;41(3):1447-1454. doi: https:\/\/doi.org\/10.3892\/ijmm.2018.3372","journal-title":"Int. J. Mol. Med."}],"container-title":["Bulletin of Experimental Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-024-06093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10517-024-06093-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-024-06093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:27:18Z","timestamp":1715927238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10517-024-06093-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6093"],"URL":"https:\/\/doi.org\/10.1007\/s10517-024-06093-0","relation":{},"ISSN":["0007-4888","1573-8221"],"issn-type":[{"value":"0007-4888","type":"print"},{"value":"1573-8221","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}